Ipilimumab clinical trials

A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.

A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

This study looks at new ways to treat advanced cancers using a combination of different medications. Researchers want to see how safe these combinations are and how well they work to shrink tumours or stop them from growing.

A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers

This study is testing a new medicine, BMS-986253, alongside existing cancer treatments (Nivolumab and Ipilimumab) for advanced cancers. Doctors want to see how safe the combined medicines are and if they help shrink tumors. It's an early-stage study to gather important information.

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

This study is looking at new treatments for advanced kidney cancer. It compares a combination of two drugs, nivolumab and cabozantinib, against a standard treatment, sunitinib, to see which works better and is safer for people who haven't had treatment before.

C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY

This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

This study looks at a new treatment for solid tumours, which are common types of cancer. It uses a patient's own immune cells, called TILs, to fight the cancer. Researchers want to see how well these cells work at shrinking tumours and keeping the cancer away.

A phase I study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with Ipilimumab in subjects with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI Trial)

This study looks at a new combination of treatments, Ipilimumab and Pluvicto, for men with very high-risk prostate cancer before they have surgery. Researchers want to see if this combination is safe and helps shrink the cancer, making surgery easier and more effective.

EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)

This study, named Nivothym, is looking at new treatments for a rare type of cancer called thymoma or thymic carcinoma. It's testing two medicines, ipilimumab and nivolumab, to see if they can help patients whose cancer has come back after chemotherapy. The main goal is to see if the cancer stays stable for at least six months.

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

This study is looking at treatments for different advanced cancers like breast, stomach, and lung cancer. It’s testing a new medicine called nivolumab, alone or with another drug, ipilimumab, to see how well they shrink tumors and if they have side effects.

(CHOPI) Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma.

This study is looking at new ways to treat advanced uveal melanoma, a type of eye cancer that has spread. It combines a liver treatment called percutaneous hepatic perfusion with two immunotherapy drugs, ipilimumab and nivolumab, to see if it's safe and helps people live longer without their cancer growing.

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer

This study looks at new drug combinations for advanced bowel cancer. It's for people whose cancer has grown or spread, and aims to see how well these new treatments shrink tumours, using drugs that boost the body's own immune system.

RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma of rare subtype

This study compares two treatments for rare advanced sarcomas: a combination of nivolumab and ipilimumab, or pazopanib alone. It aims to see which treatment best stops the cancer from growing or spreading and helps people live longer.

A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)

This study looks at a new way to treat melanoma, a type of skin cancer, using existing drugs. It combines an older chemotherapy drug (dacarbazine) with newer immunotherapy treatments (pembrolizumab, nivolumab, ipilimumab) for people whose cancer hasn't responded to immunotherapy alone. We want to see if this combination helps more people.

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

This study compares a new treatment called IMA203 with standard care for advanced skin melanoma that has already been treated. Its main goal is to see if IMA203 is more effective and safe for patients who have limited treatment options.

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

This study is looking at a new medicine called Pumitamig, by itself or with another medicine called Ipilimumab. It's for people in the UK with advanced liver cancer that can't be removed by surgery. The main goal is to see how safe and well these treatments are tolerated.

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

This study compares two drug combinations for advanced uveal melanoma. It looks at RP2 with nivolumab versus nivolumab with ipilimumab, for patients who haven't had these immune-boosting treatments before, to see which works better and is safer.

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

This study looks at a new drug, mRNA-4359, by itself and with other cancer drugs. It aims to see if it's safe and what side effects it might have in people with advanced solid tumours, which are cancers that have spread.

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

This study is looking at an experimental drug called Pumitamig, by itself or with other treatments, for people with advanced kidney cancer (renal cell carcinoma). Researchers want to see how safe and effective these treatments are.

Pan Tumor Rollover Study

This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

This study compares a new treatment, Volrustomig combined with standard chemotherapy, against existing treatments for advanced mesothelioma. It aims to see if the new combination is safer and more effective for patients whose cancer can't be removed by surgery.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

This study looks at new treatments for advanced eye melanoma that has spread. It compares a combination of two drugs (IDE196 and crizotinib) with standard treatments to see which works best and is safest for patients.

A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer

This study is looking at new drug combinations (Nivolumab and Ipilimumab, or a VEGFR tKi) for kidney cancer that has spread. It aims to see how many people respond to the treatments and how long those responses last, hoping to find better ways to fight the cancer.

Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial

This study is looking at a new combination of existing cancer drugs for people with bowel cancer that has spread and hasn't responded to earlier chemotherapy. It aims to see how well these new drug combinations control the cancer when given together.

C6461008 - AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

This study is looking at a new medicine called PF-08634404 for advanced kidney cancer. Researchers want to see if it's safe and helps shrink tumours, both on its own and when given with other common cancer drugs like ipilimumab and axitinib. It's for adults with kidney cancer that has spread.

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

This study is testing a new medicine called ODM-212 alongside existing cancer treatments for people with advanced solid tumours. It aims to check if the treatment is safe, how the body handles it, and if it helps shrink tumours or slow their growth.

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.

A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Nonsmall Cell Lung Cancer (LA NSCLC)

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.